EMA’s CHMP issued an opinion not to recommend Elevidys™ (delandistrogene moxeparvovec) for the treatment of ambulatory individuals with Duchenne muscular...
Spanning 11 studies across the U.S., Canada, Sweden, and Australia, the newly funded research explores interventions for young people dealing...
Harnessing Voice Analysis, NuCalm's Breakthrough Technology Determines Your Stress Level with Ease and Accuracy LOS ANGELES, July 23, 2025 /PRNewswire/...
BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and Inmagene Biopharmaceuticals (“Inmagene”)...
BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and Inmagene Biopharmaceuticals (“Inmagene”)...
Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences,...
WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics...
MIDDLETON, Wis., July 22, 2025 /PRNewswire/ -- Natus Medical Incorporated is continuing its commitment to innovation and expanding the functionality of...
NEW ORLEANS, July 22, 2025 /PRNewswire/ -- Answer ALS is proud to announce the launch of a groundbreaking collaborative initiative...
Powering Alzheimer's research with AI-driven insights across cognition, meaning, motor function, and speech — accelerating study recruitment and enabling more...
SANTA BARBARA, Calif., July 22, 2025 /PRNewswire/ -- WorldViz is excited to announce its seventh and most comprehensive Partners in...
IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer's disease and dementiasWASHINGTON, July 22, 2025 (GLOBE...
MALVERN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,...
Seasoned leaders bring deep expertise in neuroscience drug development, strategic growth, and corporate finance to support BioVie’s missionCARSON CITY, Nev.,...
-- Phase 1 Data Highlight RE104 Favorable Safety Profile and Short Duration Psychoactive Experience -- -- Topline Results from RECONNECT...
$2.4 million private financing plus an additional $6.8 million of proceeds due to exercise of warrants and $0.8 million from...
—Top 4% of Global Applicants Selected to Compete for $800K in Non-Dilutive Funding and Unmatched Industry Access— —Up to 13...
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s DiseaseCAMBRIDGE, Mass., July 21,...
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease CAMBRIDGE, Mass., July...
Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses...